JP6655548B2 - 細胞培養培地における使用のためのポロキサマーを調製する方法 - Google Patents

細胞培養培地における使用のためのポロキサマーを調製する方法 Download PDF

Info

Publication number
JP6655548B2
JP6655548B2 JP2016558605A JP2016558605A JP6655548B2 JP 6655548 B2 JP6655548 B2 JP 6655548B2 JP 2016558605 A JP2016558605 A JP 2016558605A JP 2016558605 A JP2016558605 A JP 2016558605A JP 6655548 B2 JP6655548 B2 JP 6655548B2
Authority
JP
Japan
Prior art keywords
poloxamer
minutes
cell culture
heated
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016558605A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017516459A5 (enExample
JP2017516459A (ja
Inventor
ガネッシュ プラサダー ヴィスヴェスヴァラン，
ガネッシュ プラサダー ヴィスヴェスヴァラン，
ロバード デーヴィッド キス，
ロバード デーヴィッド キス，
スティーヴン ジェー． マイアー，
スティーヴン ジェー． マイアー，
インチャン クォン，
インチャン クォン，
カラ カルフーン，
カラ カルフーン，
ケイト ウィンチェスター，
ケイト ウィンチェスター，
アメーリア アダムズ，
アメーリア アダムズ，
マリオン グレン，
マリオン グレン，
ステファン クーニック，
ステファン クーニック，
アラン ディーズ，
アラン ディーズ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2017516459A publication Critical patent/JP2017516459A/ja
Publication of JP2017516459A5 publication Critical patent/JP2017516459A5/ja
Application granted granted Critical
Publication of JP6655548B2 publication Critical patent/JP6655548B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/30—Post-polymerisation treatment, e.g. recovery, purification, drying
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/28—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type
    • C08G2650/50—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type containing nitrogen, e.g. polyetheramines or Jeffamines(r)
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/28—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type
    • C08G2650/58—Ethylene oxide or propylene oxide copolymers, e.g. pluronics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/50—Soluble polymers, e.g. polyethyleneglycol [PEG]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2016558605A 2014-03-25 2015-03-25 細胞培養培地における使用のためのポロキサマーを調製する方法 Active JP6655548B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461970281P 2014-03-25 2014-03-25
US61/970,281 2014-03-25
PCT/US2015/022592 WO2015148736A1 (en) 2014-03-25 2015-03-25 Methods of preparing a poloxamer for use in cell culture medium

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020017136A Division JP2020103290A (ja) 2014-03-25 2020-02-04 細胞培養培地における使用のためのポロキサマーを調製する方法

Publications (3)

Publication Number Publication Date
JP2017516459A JP2017516459A (ja) 2017-06-22
JP2017516459A5 JP2017516459A5 (enExample) 2018-05-10
JP6655548B2 true JP6655548B2 (ja) 2020-02-26

Family

ID=52824596

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016558605A Active JP6655548B2 (ja) 2014-03-25 2015-03-25 細胞培養培地における使用のためのポロキサマーを調製する方法
JP2020017136A Withdrawn JP2020103290A (ja) 2014-03-25 2020-02-04 細胞培養培地における使用のためのポロキサマーを調製する方法
JP2022157928A Active JP7472222B2 (ja) 2014-03-25 2022-09-30 細胞培養培地における使用のためのポロキサマーを調製する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020017136A Withdrawn JP2020103290A (ja) 2014-03-25 2020-02-04 細胞培養培地における使用のためのポロキサマーを調製する方法
JP2022157928A Active JP7472222B2 (ja) 2014-03-25 2022-09-30 細胞培養培地における使用のためのポロキサマーを調製する方法

Country Status (19)

Country Link
US (2) US11034793B2 (enExample)
EP (2) EP3778702B1 (enExample)
JP (3) JP6655548B2 (enExample)
KR (1) KR102352250B1 (enExample)
CN (2) CN111808276A (enExample)
AU (1) AU2015236008B2 (enExample)
BR (1) BR112016021739B1 (enExample)
CA (1) CA2943357C (enExample)
ES (1) ES2778680T3 (enExample)
HR (1) HRP20200372T1 (enExample)
IL (2) IL247902B (enExample)
MX (2) MX2016012288A (enExample)
MY (1) MY178060A (enExample)
PL (1) PL3122799T3 (enExample)
RU (1) RU2710551C2 (enExample)
SG (1) SG11201607929PA (enExample)
SI (1) SI3122799T1 (enExample)
WO (1) WO2015148736A1 (enExample)
ZA (1) ZA201606711B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020103290A (ja) * 2014-03-25 2020-07-09 ジェネンテック， インコーポレイテッド 細胞培養培地における使用のためのポロキサマーを調製する方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180125999A (ko) 2016-03-17 2018-11-26 메르크 파텐트 게엠베하 폴록사머의 정제 방법
KR102544922B1 (ko) * 2017-12-21 2023-06-16 시그마-알드리치 컴퍼니., 엘엘씨 폴록사머 조성물 및 이의 제조 및 사용 방법
WO2020013725A1 (en) * 2018-07-12 2020-01-16 Arshintseva Elena Valentinovna Thermal method for sterilizing poloxamer comprising liquid drugs
JPWO2020022511A1 (ja) * 2018-07-27 2021-08-02 味の素株式会社 動物細胞の浮遊培養用の添加物、浮遊培養用培地および浮遊培養方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE266710C (enExample)
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5531925A (en) 1991-10-04 1996-07-02 Gs Biochem Ab Particles, method of preparing said particles and uses thereof
CA2181164C (en) * 1994-01-14 2008-01-08 Arnold Horwitz Anti-gram-positive bacterial methods and materials
US5912228A (en) * 1995-01-13 1999-06-15 Xoma Corporation Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
GB9625175D0 (en) * 1996-12-04 1997-01-22 Medi Cult As Serum-free cell culture media
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
TWI367113B (en) * 2003-02-12 2012-07-01 Syncera Inc Random and non-random alkylene oxide polymer alloy compositions
AU2003900887A0 (en) * 2003-02-27 2003-03-13 Novasel Australia Pty Ltd Poloxamer emulsion preparations
US8802116B2 (en) * 2003-02-27 2014-08-12 Novasel Australia Pty. Ltd. Poloxamer emulsion preparations
US9522377B2 (en) 2003-08-04 2016-12-20 Camurus Ab Method for improving the properties of amphiphile particles
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
US20060121016A1 (en) 2004-10-18 2006-06-08 Lee Raphael C Methods and compositions for treatment of free radical injury
US9149433B2 (en) 2004-11-30 2015-10-06 Basf Corporation Method for formation of micro-prilled polymers
CN1939534B (zh) * 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
WO2008021347A2 (en) 2006-08-16 2008-02-21 Novartis Ag Method for making solid dispersions of highly crystalline therapeutic compounds
KR100932613B1 (ko) 2007-04-27 2009-12-17 한남대학교 산학협력단 고분자 용융공정을 이용한 약물전달용 생체적합성 고분자나노 미립구의 제조방법 및 그 나노 미립구
WO2009055312A1 (en) * 2007-10-22 2009-04-30 Dfb Pharmaceuticals, Inc. Process for producing a poloxamer gel
SI2574677T1 (sl) * 2007-12-27 2017-11-30 Baxalta GmbH Procesi celične kulture
WO2011077035A1 (fr) * 2009-12-23 2011-06-30 Sanofi Pasteur Procede de culture de cellules adherentes
US9629811B2 (en) * 2012-03-30 2017-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Microsphere compositions, preparation method and applications thereof
SG11201607929PA (en) * 2014-03-25 2016-10-28 Genentech Inc Methods of preparing a poloxamer for use in cell culture medium

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020103290A (ja) * 2014-03-25 2020-07-09 ジェネンテック， インコーポレイテッド 細胞培養培地における使用のためのポロキサマーを調製する方法

Also Published As

Publication number Publication date
CN111808276A (zh) 2020-10-23
ZA201606711B (en) 2019-12-18
EP3778702A1 (en) 2021-02-17
AU2015236008A1 (en) 2016-10-27
KR20160138161A (ko) 2016-12-02
RU2710551C2 (ru) 2019-12-27
EP3122799A1 (en) 2017-02-01
IL279583A (en) 2021-03-01
HRP20200372T1 (hr) 2020-06-12
AU2015236008B2 (en) 2018-12-20
RU2016141568A (ru) 2018-04-28
EP3122799B8 (en) 2020-03-11
EP3778702B1 (en) 2023-06-28
MX2021001981A (es) 2021-04-28
RU2016141568A3 (enExample) 2018-09-26
MY178060A (en) 2020-09-30
SI3122799T1 (sl) 2020-06-30
JP2023011566A (ja) 2023-01-24
EP3122799B1 (en) 2020-01-15
US20210371587A1 (en) 2021-12-02
WO2015148736A8 (en) 2016-08-18
MX2016012288A (es) 2017-01-23
IL247902B (en) 2021-01-31
IL247902A0 (en) 2016-11-30
WO2015148736A1 (en) 2015-10-01
BR112016021739A2 (pt) 2017-08-15
US11912823B2 (en) 2024-02-27
CN106414552A (zh) 2017-02-15
JP2020103290A (ja) 2020-07-09
KR102352250B1 (ko) 2022-01-17
ES2778680T3 (es) 2020-08-11
JP7472222B2 (ja) 2024-04-22
PL3122799T3 (pl) 2020-06-29
IL279583B (en) 2022-03-01
US11034793B2 (en) 2021-06-15
SG11201607929PA (en) 2016-10-28
US20170009015A1 (en) 2017-01-12
NZ725151A (en) 2021-05-28
CN106414552B (zh) 2020-08-25
JP2017516459A (ja) 2017-06-22
CA2943357C (en) 2023-06-27
BR112016021739B1 (pt) 2021-11-03
CA2943357A1 (en) 2015-10-01

Similar Documents

Publication Publication Date Title
JP7472222B2 (ja) 細胞培養培地における使用のためのポロキサマーを調製する方法
JP6591395B2 (ja) 抗酸化剤を含む細胞培養組成物およびポリペプチド産生のための方法
JP7075927B2 (ja) 緩衝剤溶液を提供するための方法及びシステム
BR112015022682B1 (pt) Método para cultivar células e para produzir uma proteína
AU2010278751B2 (en) Cell culture medium for ADAMTS protein expression
JP2022512332A (ja) 変異したｐｉｇｇｙｂａｃトランスポザーゼ
TWI736071B (zh) 於蛋白質溶液中控制雙硫鍵形成之方法
HK40038241A (en) Methods of preparing a poloxamer for use in cell culture medium
HK1233287B (en) Methods of preparing a poloxamer for use in cell culture medium
NZ725151B2 (en) Methods of preparing a poloxamer for use in cell culture medium
HK1233287A1 (en) Methods of preparing a poloxamer for use in cell culture medium
HK40008326A (en) Method and system for providing buffer solutions
HK1259741A1 (en) Serum-free cell culture medium

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180326

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190711

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200203

R150 Certificate of patent or registration of utility model

Ref document number: 6655548

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250